End of Announcement- EQS News Service.

Advanced Oncotherapy Plc Announced, in its results for the year ended 31 December 2019, that loss after tax narrowed to £20.8 (AVO.L) million from £21.1 million. The basic and diluted loss per share stood at 9.83p down from 14.05p. Separately, the company has entered into two financing agreements, providing it access to up to approximately £42 million of additional funding to further the development of the LIGHT system and advance the manufacturing of up to 30 LIGHT systems. #AVO

RNS Number: 2980 R Advanced Oncotherapy PLC 29 June 2020 The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations No. 596/ 2014. ·Completed equity investments totalling £44 m from both existing and new shareholders. ·Announced a strategic funding...

Agreements provide access to up to approximately £42 million of funding. Nerano Pharma to provide $30 million debt facility. Advanced Oncotherapy has entered into an unsecured debt facility agreement with existing supplier VDL ETG Precision BV, a subsidiary of VDL Groep BV, for €20.0 million, and has also entered into an interest-bearing secured...

RNS Number: 1610 Q Advanced Oncotherapy PLC 17 June 2020 17 June 2020. Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a...

RNS Number: 1851 P Advanced Oncotherapy PLC 08 June 2020 The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations No. 596/ 2014. With the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be...

RNS Number: 8835 O Advanced Oncotherapy PLC 03 June 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

RNS Number: 2626 O Advanced Oncotherapy PLC 29 May 2020 29 May 2020. Advanced Oncotherapy, a UK headquartered company with offices in London, Geneva, The Netherlands and in the USA, is a provider of particle therapy with protons that harnesses the best in modern technology. Advanced Oncotherapy's team "ADAM," based in Geneva, focuses on the development of a...

RNS Number: 5301 N Advanced Oncotherapy PLC 20 May 2020 TR-1: S tandard form for notification of major holdings. This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom.

RNS Number: 5530 M Advanced Oncotherapy PLC 11 May 2020 11 May 2020. Further to the Subscription announced on 9 April 2020, the Company is pleased to announce, due to additional investor demand, a further equity fundraise of £167,500, before expenses, from new and existing investors through the issue of 670,000 new ordinary shares at a price of 25 pence per share...

RNS Number: 2650 K Advanced Oncotherapy PLC 21 April 2020 21 April 2020. Notice of general meeting and posting of circular. Advanced Oncotherapy, the developer of next-generation proton therapy systems for cancer treatment, announces that further to its announcements of 9 April 2020, the Company has published a Circular to convene a General Meeting of...

Andrew Hore Quoted Micro April 13 - #ADB #ANA #AQSG #ARB #AVAP #AVO #BOU #CHH #CIR #D4T4 #EMAN #LIFE #NQMI #NTOG #SREI #RENE #SFE #SOP #SUS #TET

Advanced Oncotherapy 26p £64m (.AVOL) Has raised £14.9m at 25p. All critical components delivered to Daresbury; funding will progress assembly and validation of first LIGHT system. Documentation work for LIGHT continues despite site closures due to COVID-19.The Company was already working to a tight deadline to bring the LIGHT System into operation by the end of 2020. It now believes that the closure of these facilities will delay this objective and first patient treatment into 2021. In the meantime, the core team of the Company has shifted to focussing on finalising the documentation required for the LIGHT System to gain regulatory approval. #AVO

Advanced Oncotherapy (AVO.L): £15m fundraise and Covid-19 update Market capitalisation: £63.6m; Share price: 26p · Proton therapy developer, Advanced Oncotherapy, announced a £15m fundraise. · The funds are intended to progress the regulatory approval of LIGHT, the Group’s novel proton beam therapy system for cancer treatment. · The subscription, conditional upon shareholder approval, was completed at 25p/share. · In response to the COVID-19 pandemic, AVO noted the Daresbury Laboratory and Harley Street sites have been temporarily closed · The Company expects the first LIGHT System to become operational with first patient treatment in 2021 (previously expected end of 2020). The completion of a double-digit fundraise in current market conditions is an achievement and should ensure AVO is well capitalised for the current period of uncertainty driven by the coronavirus pandemic. The delay in first patient treatment to 2021 is unsurprising given the current lockdown conditions. LIGHT is classified as a medical device and is therefore going through the CE and FDA 510(k) pathways. Under remote working conditions the Group is still able to progress documentation work for the regulatory submission. Proton therapy has been observed to have benefits over conventional radiotherapy, such as a more focused dose of radiation to the tumour site and a reduction in damage to healthy tissue surrounding the tumour site. #AVO

RNS Number: 2935 J Advanced Oncotherapy PLC 09 April 2020 9 April 2020. Further re Subscription and Issue of Equity in lieu of fees. Further to the announcement made earlier today, Advanced Oncotherapy, the developer of next-generation proton therapy systems for cancer treatment, announces that several directors have subscribed for, in aggregate, 760,000...

RNS Number: 2933 J Advanced Oncotherapy PLC 09 April 2020 The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations No. 596/ 2014. Advanced Oncotherapy, the developer of next-generation proton therapy systems for cancer treatment, is pleased to announce an...

End of Announcement- EQS News Service.